Osborne Clarke - Netherlands has advised Myosotis Investments BV as lead investor on the €13 million Series A financing of PamDx, an innovative Dutch CRO specialising in biomarker research and in‑vitro diagnostic services. The round, which also included investment from the EIC - European Innovation Council Fund and existing shareholder, marks an important milestone in the company’s transition from breakthrough innovator to commercial‑stage diagnostics provider.

The funding will accelerate the clinical programmes and commercialisation of PamDx’s proprietary iOpener® platform, a ground-breaking new blood test designed for rapid measurement of protein kinases in cancer patients to optimize the use of immunotherapy.

Osborne Clarke - Netherlands is pleased to support Myosotis Investments on this transaction, after recently advising them on investments in Scinus Cell Expansion B.V. and Cyclomics.

The Osborne Clarke core deal team consisted of M&A/ Venture Capital Partner Herke Van Hulst and associates Angela Saldanha and Saliha El Morabit with support from Notarial Senior Associate Kristianne Voorn.

Osborne Clarke has a market-leading international venture capital practice and is widely recognised as a leading European law firm for companies operating in the life science and healthcare sector. Its sector team has a strong track record of providing highly sophisticated advice to investors and biotech clients on cutting-edge issues, across multiple service lines. They work with blue chip venture capital firms, big pharma and medical device companies in the market.